| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1357 | 2021 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 478 | 2021 |
| Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) E Grande, J Capdevila, D Castellano, A Teulé, I Durán, J Fuster, I Sevilla, ... Annals of oncology 26 (9), 1987-1993, 2015 | 141 | 2015 |
| Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors J Molina-Cerrillo, T Alonso-Gordoa, P Gajate, E Grande Cancer Treatment Reviews 58, 41-50, 2017 | 125 | 2017 |
| Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy O Martínez-Sáez, PG Borau, T Alonso-Gordoa, J Molina-Cerrillo, ... Critical reviews in oncology/hematology 111, 117-123, 2017 | 123 | 2017 |
| Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma DF McDermott, JL Lee, GA Bjarnason, JMG Larkin, RA Gafanov, ... Journal of Clinical Oncology 39 (9), 1020-1028, 2021 | 111 | 2021 |
| Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised … TK Choueiri, M Eto, R Motzer, U De Giorgi, T Buchler, NS Basappa, ... The Lancet Oncology 24 (3), 228-238, 2023 | 81 | 2023 |
| BRAF mutated colorectal cancer: New treatment approaches J Molina-Cerrillo, M San Román, J Pozas, T Alonso-Gordoa, M Pozas, ... Cancers 12 (6), 1571, 2020 | 75 | 2020 |
| Tyrosine kinase receptors in oncology J Esteban-Villarrubia, JJ Soto-Castillo, J Pozas, M San Román-Gil, ... International journal of molecular sciences 21 (22), 8529, 2020 | 74 | 2020 |
| Advances in thyroid cancer treatment: latest evidence and clinical potential T Alonso-Gordoa, JJ Díez, M Durán, E Grande Therapeutic advances in medical oncology 7 (1), 22-38, 2015 | 69 | 2015 |
| Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study A Carmona-Bayonas, P Jiménez-Fonseca, Á Lamarca, J Barriuso, ... Journal of Clinical Oncology 37 (28), 2571-2580, 2019 | 63 | 2019 |
| 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic … J Capdevila, A Teule, C López, R García-Carbonero, M Benavent, ... Annals of Oncology 31, S770-S771, 2020 | 61 | 2020 |
| DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC … E Grande, F Guerrero, J Puente, I Galante, I Duran, M Dominguez, ... Journal of Clinical Oncology 38 (15_suppl), 5012-5012, 2020 | 59 | 2020 |
| Targeting tyrosine kinases in renal cell carcinoma:“new bullets against old guys” T Alonso-Gordoa, ML García-Bermejo, E Grande, P Garrido, A Carrato, ... International journal of molecular sciences 20 (8), 1901, 2019 | 54 | 2019 |
| GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours T Alonso-Gordoa, J Capdevila, E Grande European Journal of Endocrinology 172 (1), R31-R46, 2015 | 53 | 2015 |
| Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer AG de Liano Lista, N van Dijk, GVO de Rueda, A Necchi, P Lavaud, ... European urology 77 (2), 269-276, 2020 | 48 | 2020 |
| Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience G Crespo, P Jiménez-Fonseca, A Custodio, C López, ... Future Oncology 13 (7), 615-624, 2016 | 44 | 2016 |
| Molecular mechanisms of resistance to immunotherapy and antiangiogenic treatments in clear cell renal cell carcinoma PÁ Ballesteros, J Chamorro, MS Román-Gil, J Pozas, ... Cancers 13 (23), 5981, 2021 | 38 | 2021 |
| New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects? A Barquín-García, J Molina-Cerrillo, P Garrido, D Garcia-Palos, A Carrato, ... European Journal of Internal Medicine 66, 1-8, 2019 | 37 | 2019 |
| Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced … RJ Motzer, C Porta, M Eto, T Powles, V Grünwald, TE Hutson, B Alekseev, ... Journal of Clinical Oncology 39 (6_suppl), 269-269, 2021 | 34 | 2021 |
